Mosaic Neurofibromatosis Type 1: A Systematic Review.
Confusion is widespread regarding segmental or mosaic neurofibromatosis type 1 (MNF1). Physicians should use the same terms and be aware of its comorbidities and risks. The objective of the current study was to identify and synthesize data for cases of MNF1 published from 1977 to 2012 to better understand its significance and associations. After a literature search in PubMed, we reviewed all available relevant articles and abstracted and synthetized the relevant clinical data about manifestations, associated findings, family history and genetic testing. We identified 111 articles reporting 320 individuals. Most had pigmentary changes or neurofibromas only. Individuals with pigmentary changes alone were identified at a younger age. Seventy-six percent had localized MNF1 restricted to one segment; the remainder had generalized MNF1. Of 157 case reports, 29% had complications associated with NF1. In one large case series, 6.5% had offspring with complete NF1. The terms "segmental" and "type V" neurofibromatosis should be abandoned, and the correct term, mosaic NF1 (MNF1), should be used. All individuals with suspected MNF1 should have a complete physical examination, genetic testing of blood and skin, counseling, and health surveillance.
Dermatology Section, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.|Department of Pediatric Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Maria Teresa
MT
García-Romero
Department of Pediatric Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Patricia
P
Parkin
Dermatology Section, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.|Department of Pediatric Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Irene
I
Lara-Corrales
D006801:Humans; D009030:Mosaicism; D009456:Neurofibromatosis 1 / Q000150:complications / Q000175:diagnosis*